

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida ID5089

## Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Farco-Pharma (intravesical oxybutynin hydrochloride)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Aspire</li> <li>• Back Up</li> <li>• Bladder and Bowel Community</li> <li>• Bladder and Bowel UK</li> <li>• Bladder Health UK</li> <li>• Brain and Spine Foundation</li> <li>• Neurological Alliance</li> <li>• Brain Charity</li> <li>• Shine</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Spinal Injuries Association</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>• Association for Continence Advice</li> <li>• Association of British Neurologists</li> <li>• British Association of Paediatric Nephrology</li> <li>• British Association of Paediatric Urologists</li> <li>• British Association of Urological Nurses</li> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Paediatric Neurology Association</li> <li>• British Society of Urogynaecology</li> <li>• Institute of Neurology</li> <li>• MASCIP</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Spinal Cord Injury Unit for Northern Ireland, Musgrave Park Hospital</li> <li>• Welsh Health Specialised Services Committee</li> <li>• Welsh Spinal Cord Injury Rehabilitation Centre, Rookwood Hospital</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• AbbVie (botulinum toxin type A)</li> <li>• Astellas Pharma (mirabegron)</li> <li>• Croma Pharma (botulinum toxin type A)</li> <li>• Galderma (botulinum toxin type A)</li> <li>• Ipsen (botulinum toxin type A)</li> <li>• Merz Pharma (botulinum toxin type A)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Incontinence Review Group</li> </ul>

Provisional stakeholder list for the evaluation of oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida ID5089

Issue date: July 2022

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Neonatal and Paediatric Pharmacists Group</li> <li>• Primary Care and Community Neurology Society</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Paediatrics &amp; Child Health</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Continence Society</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• Duke of Cornwall Spinal Treatment Centre, Salisbury District Hospital</li> <li>• Golden Jubilee North East Regional Spinal Injuries Centre, James Cook University Hospital</li> <li>• London Spinal Cord Injury Centre, Royal National Orthopaedic Hospital</li> <li>• Midlands Centre for Spinal Injuries, Robert Jones &amp; Agnes Hunt Hospital</li> <li>• National Spinal Injuries Centre, Stoke Mandeville Hospital</li> <li>• NHS England</li> <li>• NHS Herts Valleys CCG</li> <li>• NHS Telford &amp; Wrekin CCG</li> <li>• Northwest Regional Spinal Injuries Centre, Southport &amp; Formby Hospital</li> <li>• Princess Royal Spinal Injuries Centre, Northern General Hospital</li> <li>• Welsh Government</li> <li>• Yorkshire Regional Spinal Injuries Centre, Pinderfields Hospital</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Kidney and Transplant Group</li> <li>• Cochrane UK</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Hospital for Neurology and Neurosurgery</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations

from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.